Suppression of graft-versus-host disease and amplification of graft- versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation

Journal of Clinical Investigation

Volumn 101, Issue 9, 1998, Pages 1835-1842

  Asai, Osamu ^a   Longo, Dan L ^c   Tian, Zhi Gang ^b   Hornung, Ronald L ^b   Taub, Dennis D ^c   Ruscetti, Francis W ^a   Murphy, William J ^b,d  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

^c NATIONAL INSTITUTE ON AGING   (United States)

^d NONE   (United States)

Author keywords

Bone marrow transplantation; Cytokines; Graft versus host disease; Immunotherapy; NK cell

Indexed keywords

ALLOGENIC BONE MARROW TRANSPLANTATION; ANIMAL CELL; ARTICLE; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL;

EID: 0032080398     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI1268     Document Type: Article

References (24)

1. Bortin, M.M., M.M. Horowitz, and A.A. Rimm. 1992. Increasing utilizations of allogeneic bone marrow transplantation: results of the 1988-1990 survey. Ann. Intern. Med. 116:505-509.
2. Armitage, J.O. 1994. Bone marrow transplantation. N. Engl. J. Med. 330: 827-829.
3. Storb, R. 1995. Bone marrow transplantation. Transplant. Proc. 27:2649-2652.
4. Ferrera, J.L., and H.J. Deeg. 1991. Graft-versus-host disease. N. Engl. J. Med. 324:667-672.
5. Goldman, J.M., R.P. Gale, M.M. Horowitz, J.C. Biggs, R.E. Champlin, E. Gluckman, R.G. Hoffmann, S.J. Jacobsen, A.M. Marmont, P.B. McGlave, et al. 1988. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: increased risk of relapse associated with T cell-depletion. Ann. Intern. Med. 108:806-811.
6. Marmont, A.M., M.M. Horowitz, R.P. Galem, K. Sobocinski, R.C. Ash, D.W. van Bekkum, R.E. Champlin, K.A. Dicke, J.M. Goldman, R.A. Good, et al. 1991. T-cell depletion of HLA-identical transplants in leukemia. Blood. 78: 2120-2123.
7. Murphy, W.J., C.W. Reynolds, P. Tiberghien, and D.L. Longo. 1993. Natural killer cells and bone marrow transplantation. J. Natl. Cancer Inst. 85:1475-1480.
8. Murphy, W.J., J.R. Keller, C.L. Harrison, H.A. Young, and D.L. Longo. 1992. Interleukin-2-activated natural killer cells can support hematopoiesis in vitro and promote marrow engraftment in vivo. Blood. 80:670-677.
9. Levitt, L.J. 1991. Production of granulocyte/macrophage-colony-stimulating factor by human natural killer cells: modulation by the p75 subunit of the interleukin 2 receptor and by the CD2 receptor. J. Clin. Invest. 88:67-75.
10. Murphy, W.J., M. Bennett, V. Kumar, and D.L. Longo. 1992. Donor-type activated natural killer cells promote marrow engraftment and B cell development during allogeneic bone marrow transplantation. J. Immunol. 148: 2953-2960.
11. Dasch, J.R., D.R. Pace, W. Waegell, D. Inenaga, and L. Ellingsworth. 1984. Monoclonal antibodies recognizing transforming growth factor-β. J. Immunol. 142:1536-1540.
12. Yamamoto, H., M. Hirayama, C. Genyeam, and J. Kaplan. 1994. TGF-β1 mediates natural suppressor activity of IL-2-activated lymphocytes. J. Immunol. 152:3842-3849.
13. + cells of donor origin. Transplantation (Baltimore). 45:586-590.
14. Sykes, M., M.L. Romick, and D.H. Sachs. 1990. Interleukin 2 presents graft-vs-riost disease while preserving the graft-vs-leukemia effect of allogeneic T cells. Proc. Natl. Acad. Sci. USA. 87:5633-5638.
15. Sykes, M., G.L. Szot, P.L. Nguyen, and D.A. Pearson. 1995. Interleukin-12 inhibits murine graft-versus-host disease. Blood. 86:2429-2438.
16. Favrot, M.C., D. Floret, S. Negrier, P. Cochat, E. Bouffet, Z. Dacheng, C.R. Franks, T. Bijman, M. Brunat-Mentigny,I. Philip, and T. Philip. 1989. Systemic interleukin-2 therapy in children with progressive neuroblastoma after high dose chemotherapy and bone marrow transplantation. Bone Marrow Transplant. 4:499-503.
17. Sykes, M., and V.S. Abraham. 1992. The mechanism of IL-2 mediated protection against GVHD in mice. II. Protection occurs independently of NK/ LAK cells. Transplantation (Baltimore). 53:1063-1070.
18. Sykes, M., D.A. Pearson, and G.L. Szot. 1995. IL-2-induced GVHD protection is not inhibited by cyclosporin and is maximal when IL-2 is given over a 25 h period beginning on the day following bone marrow transplantation. Bone Marrow Transplant. 15:395-399.
19. Ruscetti, F.W., and M.A. Palladino. 1991. Transforming growth factor-β and the immune system. Prog. Growth Factor Res. 3:159-162.
20. Trinchieri, G. 1989. Biology of natural killer cells. Adv. Immunol. 47: 187-196.
21. Habu, S., H. Fukai, K. Shimamura, M. Kasai, Y. Nagai, K. Okimura, and N. Tamaoki. 1981. In vivo effects of anti-asialo GM1. I. Reduction of NK activity and enhancement of transplanted tumor growth in nude mice. J. Immunol. 127:34-38.
22. Mowat, A.M. 1989. Antibodies to IFN-γ prevent immunologically mediated intestinal damage in murine graft-versus-host reaction. Immunol. 68:18-24.
23. Zeis, M. 1995. Allogeneic NK cells as potent antileukemic effector cells after allogeneic bone marrow transplantation in mice. Transplantation (Baltimore). 59:1734-1736.
24. Glass. B., L. Uharek, M. Zeis, H. Loeffler, W. Mueller-Ruchholtz, and W. Gassman. 1996. Graft-versus-leukaemia activity can be predicted by natural cytotoxicity against leukaemia cells. Br. J. Haematol. 93:412-420.